Parkinson's Disease Trial, Recruiting NCT06772220 Sponsor: Oregon Health and Science University Condition: Parkinson's Disease
Back to Parkinsons Disease

Parkinson's Disease Trial, Recruiting

NCT06772220
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been diagnosed with probable Parkinson's Disease based on recognised medical guidelines.
  • You are currently taking levodopa (a common Parkinson's medication) at a dose of at least 300 mg per day.
  • You scored 15 or higher on a standard memory and thinking test called the Montreal Cognitive Assessment.
  • You are able to understand and agree to take part in the study on your own.
  • You are between 40 and 90 years of age.
  • Your kidneys are working at a sufficient level, based on a blood test result (confirm with trial site).
  • You do not have a history of uncontrolled high blood pressure.
  • You are not currently using insulin.

Who may not be able to join:

  • No specific exclusion criteria have been listed for this trial (confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Joseph Quinn, MD, Oregon Health & Science University (OHSU)

Phone: 503-501-8478

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
5 March 2024
Est. completion
31 December 2025

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Hyperhomocysteinemia and B vitamin deficiency; Hyperhomocysteinemia and B vitamin deficiency; Hyperhomocysteinemia and B vitamin deficiency

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov